



March 1, 2018

**Mitsubishi Tanabe Pharma Group started marketing  
CANAGLU<sup>®</sup> Tablets 100mg, a treatment agent for type 2 diabetes  
mellitus in Taiwan**

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; President & Representative Director: Masayuki Mitsuka) announced today that consolidated subsidiary Tai Tien Pharmaceuticals Co., Ltd. (Head Office: Taipei, Taiwan; General Manager: Hitoshi Kawabe) has started marketing CANAGLU<sup>®</sup> Tablets 100mg (generic name: canagliflozin) for an indication of type 2 diabetes mellitus today.

CANAGLU<sup>®</sup>, which was discovered in Japan by Mitsubishi Tanabe Pharma, inhibits sodium glucose co-transporter 2 (SGLT2), a transporter involved in the reabsorption of glucose in the proximal renal tubules of the kidneys; suppresses the reabsorption of glucose; and promotes the excretion of excessive glucose into the urine, and as a result, lowers blood glucose.

Through licensees, CANAGLU<sup>®</sup> has been approved in more than 80 countries around the world. Following Japan, Taiwan is the second market in which CANAGLU<sup>®</sup> is sold by the Mitsubishi Tanabe Pharma Group.

The number of diabetes patients in Taiwan has been increasing in recent years, and that trend is expected to continue.

Tai Tien Pharmaceuticals, which was established in 1987, has marketed such products as HERBESSER<sup>®</sup>, CONCOR<sup>®</sup> (Japan name: MAINTATE<sup>®</sup>), and LIVALO<sup>®</sup> and has built a foundation in the field of lifestyle diseases. Leveraging that foundation, taking this opportunity, the Group will contribute to treatment of patients with type 2 diabetes mellitus.

Moving forward, Mitsubishi Tanabe Pharma will continue working to implement business activities that facilitate the rapid delivery of better drugs to patients around the world more quickly.

**Mitsubishi Tanabe Pharma Corporation  
Corporate Communications Department**

Media contacts: TEL:+81 6 6205 5119

Investor contacts: TEL:+81 6 6205 5110